By Michael Erman NEW YORK, June 6 (Reuters) - Pfizer presented data on Saturday that showed a monthly dose of an experimental ...

Pfizer (PFE) stock is in focus as mid-stage trial data support a once-monthly dosing regimen for GLP-1 therapy berobenatide.

On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it ...

NEW YORK, N.Y. — Pfizer announced Wednesday that data shows a third dose of its COVID-19 vaccine can “strongly” boost protection against the highly transmissible delta variant. The pharmaceutical and ...

Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly ...

Data demonstrated proof-of-concept for berobenatide as a first-in-class monthly GLP-1 RA peptide with competitive weight loss ...

Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an ...

Roche Holding AG and Pfizer Inc. are aggressively advancing obesity and T2D pipelines to capture share in the surging GLP-1 ...

LOS ANGELES -- The COVID-19 vaccines made by Pfizer and Moderna both require two doses to be administered, several weeks apart, for them to be fully effective. But there has been some scientific ...

PHILADELPHIA -- To help fend off another wave of Covid-19, people will need a fourth dose of vaccine, Pfizer CEO Albert Bourla said Sunday. "Many variants are coming, and Omicron was the first one ...